This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
ENDP.Q Stoklara Genel Bakış
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally.
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 0/6 |
Endo Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$0.0006 |
| 52 Haftanın En Yüksek Seviyesi | US$0.08 |
| 52 Haftanın En Düşük Seviyesi | US$0.000001 |
| Beta | 0.80 |
| 11 Aylık Değişim | 50.00% |
| 3 Aylık Değişim | 0% |
| 1 Yıllık Değişim | -98.91% |
| 33 Yıllık Değişim | -99.99% |
| 5 Yıllık Değişim | -99.99% |
| Halka arzdan bu yana değişim | -100.00% |
Son Haberler & Güncellemeler
Recent updates
Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg
Aug 16Endo International sees 23% rise on 3x higher than normal volume
Aug 03Endo outperforms defying bankruptcy fears and generic entry
Jul 25Endo weighs bankruptcy filing without opioid settlement - WSJ
Jul 12Endo International cools off, giving back some of its 85% Tuesday gain
Jun 29Endo: Stick A Fork In It
May 10Endo: About As Bad As It Gets
Mar 07Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year
Dec 16Endo: A Win In California But Equity Value Still A Question
Nov 02Endo International: Loses Vasostrict Trial
Aug 31Endo International: Hires Restructuring Advisor
Aug 20Endo International: All About Ongoing Litigation
Aug 07Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road
Jul 15Endo International: Bankruptcy Seems Like The Only Practical Option
Jun 30Endo International wins FDA approval for Micafungin new formulation
Jun 17Endo International plc 2021 Q1 - Results - Earnings Call Presentation
May 07Radius Health partners with Endo unit for abaloparatide in Canada
Jan 05Hissedar Getirileri
| ENDP.Q | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | 0% | -3.7% | -1.6% |
| 1Y | -98.9% | 17.2% | 30.8% |
Getiri vs. Endüstri: ENDP.Q underperformed the US Pharmaceuticals industry which returned 12.5% over the past year.
Getiri vs Piyasa: ENDP.Q underperformed the US Market which returned 22.8% over the past year.
Fiyat Oynaklığı
| ENDP.Q volatility | |
|---|---|
| ENDP.Q Average Weekly Movement | 207.3% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
İstikrarlı Hisse Senedi Fiyatı: ENDP.Q's share price has been volatile over the past 3 months.
Zaman İçindeki Volatilite: ENDP.Q's weekly volatility has increased from 125% to 207% over the past year.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1997 | 2,931 | Blaise Coleman | www.endo.com |
Endo Inc. Temel Bilgiler Özeti
| ENDP.Q temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$141.13k |
| Kazançlar(TTM) | -US$2.45b |
| Gelir(TTM) | US$2.01b |
0.0x
P/S Oranı0.0x
F/K OranıENDP.Q aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ENDP.Q gelir tablosu (TTM) | |
|---|---|
| Gelir | US$2.01b |
| Gelir Maliyeti | US$941.90m |
| Brüt Kâr | US$1.07b |
| Diğer Giderler | US$3.52b |
| Kazançlar | -US$2.45b |
Son Raporlanan Kazançlar
Dec 31, 2023
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -10.41 |
| Brüt Marj | 53.17% |
| Net Kâr Marjı | -121.69% |
| Borç/Özkaynak Oranı | -123.5% |
ENDP.Q uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün